Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVO
- Rev/Share 70.1487
- Book/Share 37.7947
- PB 9.3335
- Debt/Equity 0.5906
- CurrentRatio 0.784
- ROIC 0.3934
- MktCap 1567501674741.4292
- FreeCF/Share 13.9401
- PFCF 25.2868
- PE 14.1233
- Debt/Assets 0.2059
- DivYield 0.0303
- ROE 0.7786
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | NVO | HSBC Securities | Hold | Buy | -- | -- | Oct. 1, 2025 |
| Downgrade | NVO | Morgan Stanley | Equal Weight | Underweight | -- | $47 | Sept. 29, 2025 |
| Upgrade | NVO | Berenberg | Hold | Buy | -- | -- | Sept. 17, 2025 |
| Upgrade | NVO | Rothschild & Co Redburn | Neutral | Buy | -- | -- | Sept. 16, 2025 |
| Upgrade | NVO | Bernstein | Market Perform | Outperform | -- | -- | Sept. 9, 2025 |
| Upgrade | NVO | BNP Paribas Exane | Underperform | Neutral | -- | $54 | Aug. 13, 2025 |
| Downgrade | NVO | UBS | Buy | Neutral | -- | -- | Aug. 5, 2025 |
| Downgrade | NVO | HSBC Securities | Buy | Hold | -- | $57 | July 31, 2025 |
| Downgrade | NVO | Barclays | Overweight | Equal Weight | -- | -- | July 30, 2025 |
| Downgrade | NVO | BMO Capital Markets | Outperform | Market Perform | -- | $64 | April 17, 2025 |
News
NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit
Published: August 27, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 27, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 2025, both dates inclusive (the "Class Period"), of the important September 30, 2025 lead plaintiff deadline. So What: If you purchased Novo Nordisk securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Novo Nordisk A/S (NVO) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: August 27, 2025 by: PRNewsWire
Sentiment: Neutral
BENSALEM, Pa. , Aug. 27, 2025 /PRNewswire/ -- The Law Offices of Howard G.
Read More
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock is a Safer Bet?
Published: August 27, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO and VKTX face setbacks and rising competition as they battle for ground in the GLP-1 obesity market.
Read More
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Published: August 27, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Novo between May 7, 2025, to July 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Aug. 27, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Novo Nordisk A/S ("Novo" or the …
Read More
Form Health Selected for Novo Nordisk's NovoCare® Platform to Expand Access to Science-Based Obesity Care Across the United States
Published: August 27, 2025 by: Business Wire
Sentiment: Neutral
BOSTON--(BUSINESS WIRE)--Today, Form Health, the leading provider of science-based obesity and cardiometabolic care in the United States, announced its selection as a healthcare provider option on Novo Nordisk's NovoCare® platform. NovoCare® connects patients seeking treatment for chronic care with trusted healthcare providers, and Form Health's inclusion will expand access to high-quality, evidence-based care delivered by trained Obesity Medicine Clinicians and Registered Dietitians. The relat.
Read More
Can Novo Nordisk Offset GLP-1 Pressures With Rare Disease Wins?
Published: August 26, 2025 by: Zacks Investment Research
Sentiment: Neutral
NVO faces slowing GLP-1 momentum but leans on rare disease wins and new Wegovy approval to bolster growth.
Read More
Deadline Alert: Novo Nordisk A/S (NVO) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: August 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming September 30, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO) securities between May 7, 2025, to July 28, 2025, inclusive (the “Class Period”).
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
Published: August 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
Published: August 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Novo Nordisk Roars Back: 6 Catalysts Driving the Pharma's Path to Dominance
Published: August 22, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Key Points in This Article: Novo Nordisk (NVO) pioneered GLP-1 drugs with Ozempic and Wegovy, but lost ground to Eli Lilly's Mounjaro and Zepbound.
Read More
Novo Nordisk A/S (NVO) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: August 22, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Aug. 22, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO). IF YOU SUFFERED A LOSS ON YOUR NOVO NORDISK INVESTMENTS, CLICK HERE BEFORE SEPTEMBER 30, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?
Read More
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Published: August 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo To Contact Him Directly To Discuss Their Options
Read More
September 30, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against NVO
Published: August 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Novo investors who were adversely affected by alleged securities fraud between May 7, 2025 and July 28, 2025.
Read More
Novo Nordisk: This Options Strategy Was Profitable Even With The Stock Down
Published: August 22, 2025 by: Seeking Alpha
Sentiment: Negative
Novo Nordisk's economic moat is eroding due to increased competition and US drug price pressures, but growth in international markets and new launches support the outlook. My updated fair value estimate is $67.65, down from $83, reflecting lowered guidance but still offering about 25% upside from current levels. I continue to manage risk with a Put Spread strategy, adapting positions as the stock declines, which has delivered a solid 16-20% ROI even with the stock down ~20%.
Read More
The Gross Law Firm Notifies Novo Nordisk A/S Investors of a Class Action Lawsuit and Upcoming Deadline – NVO
Published: August 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).
Read More
DEADLINE ALERT for FLYW, LMT, SOC, NVO: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
Published: August 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
BENSALEM, Pa., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Read More
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Published: August 21, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Novo To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Novo between May 7, 2025, to July 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Aug. 21, 2025 /PRNewswire/ -- August 18, 2025 / PR Newswire / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating …
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
Published: August 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (Aug 2025)
Published: August 21, 2025 by: 24/7 Wall Street
Sentiment: Negative
Among all the weight loss drugs, Ozempic has become a phenomenon. With as much as $17 billion in sales in 2024 and over $10 billion in the first half of 2025, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO).
Read More
Fat busters having a muted impact consumer sector. But for how long?
Published: August 21, 2025 by: Proactive Investors
Sentiment: Negative
Fine dining under pressure, beer sales at risk, and snack makers bracing for a shake-up. The rise of GLP-1 weight-loss drugs is starting to ripple through the consumer economy.
Read More
DEADLINE ALERT for SOC, LMT, NVO, and LINE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
Published: August 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Aug. 20, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Read More
Novo Nordisk halts hiring as new CEO's restructuring continues
Published: August 20, 2025 by: Proactive Investors
Sentiment: Negative
Novo Nordisk has initiated a hiring freeze as it looks to control costs under new boss Maziar Mike Doustdar. All markets and departments, apart from business-critical roles, will be affected by the pause, the company said.
Read More
Novo Nordisk to present Wegovy® and Ozempic® data showing life-saving cardiovascular benefits for people living with obesity and type 2 diabetes at the European Society of Cardiology Congress 2025
Published: August 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Bagsværd, Denmark, 20 August 2025 – Novo Nordisk today announced new data showing the cardiovascular protective benefits of Wegovy ® and Ozempic ® will be presented at the European Society of Cardiology (ESC) Congress 2025 from 29 August to 1 September in Madrid, Spain. New data will also include perspectives on the role of inflammation in a condition called atherosclerotic cardiovascular disease (ASCVD).
Read More
Deadline Alert: Novo Nordisk A/S (NVO) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: August 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming September 30, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO) securities between May 7, 2025, to July 28, 2025, inclusive (the “Class Period”).
Read More
Novo Nordisk: Market Still Pricing It At Crisis Valuations
Published: August 18, 2025 by: Seeking Alpha
Sentiment: Neutral
Novo Nordisk A/S is facing an unprecedented crisis of confidence as the tumble in its valuations reached extremely fearful levels. Novo remains the global leader in diabetes and obesity drugs, with strategic U.S. manufacturing expansion. Novo's free cash flow margins could recover through 2027 as it expands its manufacturing to take on Lilly and peers.
Read More
From Doubt To Action: Why I Bought Novo Nordisk After Earnings
Published: August 18, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk A/S Q2 earnings were solid, but the guidance disappointed. My investment decision was based on a long-term outlook rather than this single quarter. Novo Nordisk's narrative shifted rapidly from crisis to opportunity due to underwhelming Eli Lilly trial results and Wegovy's new FDA approval for liver disease. NVO stock now trades at a deep discount, with valuation metrics at half their historical averages, despite maintaining strong revenue growth and innovation momentum.
Read More
GLP-1 drug Wegovy approved to treat liver disease, what's driving Q2 earnings results
Published: August 18, 2025 by: Yahoo Finance
Sentiment: Positive
Morning Brief anchor Julie Hyman breaks down the latest market news for August 18, 2025. Novo Nordisk's weight loss drug Wegovy is the first GLP-1 drug approved to treat liver disease.
Read More
INVESTOR REMINDER: Berger Montague Notifies Novo Nordisk A/S (NYSE: NVO) Investors of a Class Action Lawsuit and Deadline
Published: August 18, 2025 by: PRNewsWire
Sentiment: Neutral
PHILADELPHIA , Aug. 18, 2025 /PRNewswire/ -- Berger Montague PC is investigating claims under the federal securities laws against Novo Nordisk A/S (NYSE: NVO) ("Novo" or the "Company"), a global pharmaceutical company, headquartered in Denmark, after a class action lawsuit was filed against Novo. Investor Deadline: Investors who purchased or acquired Novo securities between May 7, 2025 through July 28, 2025 (the "Class Period"), may, no later than September 30, 2025 , seek to be appointed as a lead plaintiff representative of the class.
Read More
Novo Nordisk's Loss Is Eli Lilly's Gain, And Vice Versa
Published: August 18, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk A/S's FDA approval for Wegovy in MASH and aggressive Ozempic pricing boost its position, despite recent stock declines and competitive pressure from Eli Lilly and Company. Both NVO and LLY face regulatory headwinds from U.S. drug pricing demands, but I believe much of the bad news is already priced in for both. Novo's strategic pricing, strong clinical data, and attractive valuation make it my preferred long-term pick, though both stocks offer upside from current levels.
Read More
Novo Nordisk to sell weight-loss drug for $499 to eligible customers
Published: August 18, 2025 by: Fox Business
Sentiment: Positive
Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through multiple pharmacy platforms.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Lars Fruergaard Jorgensen
- Employees 77406